Leerink Partners Raises LLY Price Target to $1,316

On October 21, 2026, Leerink Partners maintained its Outperform rating on Eli Lilly and Company (NYSE:LLY) while nudging its price target from $1,309.00 up to $1,316.00. According to the firm's research note, the revised target sits modestly above the recent trading price, reflecting the analyst's constructive outlook on the drug maker.

LLY Eli Lilly and Company

$1,306.74 ▲ +21.54% year to date

1M 3M YTD

Daily close · Oct 22, 2026

{Firm}'s Call on {Company}

Leerink Partners kept an upbeat stance on the pharmaceutical firm with its Outperform rating on October 21, 2026. The firm moved its target from $1,309.00 to $1,316.00. Other Wall Street firms have also updated their views recently, including JP Morgan maintaining an Overweight rating with a $1,500.00 target on September 28, 2026, Morgan Stanley keeping an Overweight rating with a $1,430.00 target on October 7, 2026, Cantor Fitzgerald maintaining an Overweight rating with a $1,440.00 target on October 8, 2026, and RBC Capital reiterating an Outperform rating with a $1,500.00 target on October 12, 2026. Across the board, thirty analysts hold a buy consensus on the stock, with a mean price target of $1,328.05.

Other Institutional Activity in {Company}

Institutional investors have been actively shifting their positions in the pharmaceutical giant. Kmg Fiduciary Partners trimmed its holdings by 1,253 shares, ending with 23,393 shares valued at about $27.07 million. Assenagon Asset Management S.A. grew its stake by 283,911 shares, bringing its total to 784,936 shares worth about $908.23 million. PensionDanmark Pensionsforsikringsaktieselskab reduced its holdings by 3,570 shares to finish with 145,819 shares valued at roughly $168.72 million. James Hambro & Partners added 507 shares to own 1,831 shares worth approximately $2.12 million. Annex Advisory Services significantly expanded its position by adding 29,346 shares for a total of 33,181 shares valued at about $38.39 million.

Eli Lilly and Company Stock Up 2.0%

Eli Lilly shares recently traded around $1,270.86 as of October 21, 2026, sitting below the prior close of $1,282.22 on October 20, 2026. The stock trades well above both its 50-day moving average of $1,181.44 and its 200-day moving average of $1,080.74, while hovering near its 52-week high of $1,292.65.

Recent Earnings

Eli Lilly reported trailing twelve month revenue of $79.67 billion and earnings of $29.79 per share. The company posted a net profit margin of 33.5% and a return on equity of 102.3%, with year-over-year revenue growth reaching 47.7%. The next earnings release is scheduled for October 29, 2026.

Dividend

The company pays an annual dividend rate of $6.92 per share, translating to a dividend yield of 0.56% with a payout ratio of 21.7%.

Insider Buying and Selling at Eli Lilly and Company

Company insiders have executed several transactions in recent months. General Counsel Anat Hakim sold 5,000 shares on August 7, 2026, at an average price of $1,190.00, totaling $5.95 million. Officer Donald A Zakrowski sold 2,000 shares on August 10, 2026, at $1,185.01 per share for a total of $2.37 million. Officer Patrik Jonsson sold 6,500 shares on August 17, 2026, at $1,175.10 per share for a total value of $7.64 million.

About {Company}

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. Headquartered in Indianapolis, Indiana, the firm focuses on delivering medical treatments across major therapeutic areas, supporting its valuation of over $1.1 trillion.

Bottom Line

Investors will look toward the upcoming earnings report on October 29, 2026, for fresh updates on drug sales and pipeline progress. Wall Street continues to monitor how shares trade relative to updated price targets from firms like Leerink Partners.